Radiopharm (RADX) Theranostics announced the completion of enrollment for the second cohort of patients in the Phase 1 dose escalation trial of 177Lu-RAD204 in PD-L1 positive advanced cancers, including non-small cell lung cancer, small cell lung cancer, triple-negative breast cancer, cutaneous melanoma, head and neck squamous cell carcinoma and endometrial cancer. The open-label Phase 1 trial, entitled “Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumors,” is a first-in-human study to evaluate the safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD2041 in eligible individuals with PD-L1 expressing advanced cancers.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RADX:
- Radiopharm Theranostics Announces Extraordinary General Meeting for Shareholder Resolutions
- Radiopharm Theranostics Limited: Promising Financial and Clinical Outlook Justifies Buy Rating
- Radiopharm Theranostics Announces November AGM with Key Resolutions
- Radiopharm provides update on pipeline of clinical programs
- Radiopharm launches A$5M share purchase plan